FDA approves GSK RSV vaccine for adults 50 to 59

The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

Related Keywords

United States ,United Kingdom ,Japan ,Americans ,British ,Phil Dormitzer ,Luke Miels ,Pfizer ,Drug Administration On ,Centers For Disease ,Drug Administration ,Disease Control ,Commercial Officer Luke Miels ,